UiPath Inc
NYSE:PATH
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
UiPath Inc
NYSE:PATH
|
US |
|
Corcept Therapeutics Inc
NASDAQ:CORT
|
US |
|
A
|
Aflac Inc
XMUN:AFL
|
US |
|
I
|
Itochu Corp
XMUN:IOC
|
JP |
|
Alpha Services and Holdings SA
F:ACBB
|
GR |
|
I
|
Itochu Corp
OTC:ITOCF
|
JP |
|
Itochu Corp
F:IOC0
|
JP |
|
Bankinter SA
F:BAKA
|
ES |
|
A
|
Adidas AG
XMUN:ADS
|
DE |
|
B
|
Bayan Resources Tbk PT
XMUN:BNB
|
ID |
Wall St Price Targets
PATH Price Targets Summary
UiPath Inc
According to Wall Street analysts, the average 1-year price target for PATH is 13.526 USD with a low forecast of 11.09 USD and a high forecast of 17.85 USD.
Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What you see on other sites is mostly sourced from sell-side analysts.
What is PATH's stock price target?
Price Target
13.526
USD
According to Wall Street analysts, the average 1-year price target for PATH is 13.526 USD with a low forecast of 11.09 USD and a high forecast of 17.85 USD.
What is the Revenue forecast for UiPath Inc?
Projected CAGR
10%
Over the last 6 years, the compound annual growth rate for Revenue has been 30%. The projected CAGR for the next 3 years is 10%.
What is the Gross Profit forecast for UiPath Inc?
Projected CAGR
9%
Over the last 6 years, the compound annual growth rate for Gross Profit has been 30%. The projected CAGR for the next 3 years is 9%.
What is the Operating Income forecast for UiPath Inc?
Projected CAGR
109%
The compound annual growth rate for Operating Income over the next 3 years is 109%.
What is the Pre-Tax Income forecast for UiPath Inc?
Projected CAGR
84%
The compound annual growth rate for Pre-Tax Income over the next 3 years is 84%.
What is the Net Income forecast for UiPath Inc?
Projected CAGR
26%
The compound annual growth rate for Net Income over the next 3 years is 26%.
